珍寶島(603567.SH):取得藥品補充申請批件 大大豐富公司中成藥的產品管線
格隆匯4月5日丨珍寶島(603567.SH)公佈,近日,公司收到國家藥品監督管理局(“藥監局”)下發的《藥品補充申請批准通知書》,具體情況如下:
批件的主要內容:





經公司總經理辦公會審議通過,2021年9月公司與黑龍江省松花江藥業有限公司(“松花江藥業”)簽訂了《藥品上市許可持有人轉讓合同》,松花江藥業將包含上述35個品種在內的共計37箇中成藥品種的藥品上市許可持有人轉讓給珍寶島,同時變更生產地址為珍寶島指定的符合GMP標準的生產場地。藥品情況如下:






注:以上市場情況數據來源為藥監局米內網、國家藥品監督管理局。
上述《藥品補充申請批件》的取得,大大豐富了公司中成藥的產品管線,對於公司中藥產業高質量發展將起到很好的推動作用,有望提高公司整體盈利水平。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.